Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and prospectively select participants based on PTGR1 overexpression and DNA-damage-repair deficiency.
This clearance is significant because LP-184 targets a patient population with high unmet need—those who have progressed on or are ineligible for current standard-of-care therapies. By using a biomarker-guided approach, Lantern aims to identify patients most likely to respond, which could improve trial success rates and accelerate development. The trial further advances Lantern's AI-driven precision oncology strategy through its proprietary RADR platform.
The EMA's decision also underscores the growing acceptance of AI-guided drug development in regulatory processes. Lantern's RADR platform uses machine learning to analyze genomic data and predict drug sensitivity, potentially reducing the time and cost of clinical trials. If successful, LP-184 could become a new treatment option for bladder cancer, which is the 10th most common cancer worldwide with limited effective therapies after first-line treatment.
Lantern's clinical pipeline includes other candidates such as LP-284 for hematologic and solid tumors, and LP-300 being evaluated in the HARMONIC Phase 2 trial for never-smoker lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. Additionally, the company's withZeta.ai platform is now commercially available as a subscription-based research tool, representing a new revenue stream.
The announcement positions Lantern to potentially address a significant gap in bladder cancer treatment. According to the American Cancer Society, about 83,190 new cases of bladder cancer are expected in the United States in 2024, and many patients relapse after initial therapy. The biomarker-driven approach could help spare patients from ineffective treatments and side effects.
For more information, the full press release is available at https://ibn.fm/6ku4F. Updates on Lantern Pharma are also available at their newsroom: https://ibn.fm/LTRN.
